CORE Appoints Dr. Alex Hui as Head of Biosciences
Tuesday, January 11 2022 | 08 h 57 min | Appointments, News, Press Release
The Centre for Ocular Research & Education (CORE) has appointed Alex Hui, OD, PhD, FAAO, as head of Biosciences. Dr. Hui is currently a senior lecturer at the School of Optometry and Vision Science at UNSW Sydney. He will soon relocate to CORE’s facility in Waterloo, Ontario, Canada.
“Dr. Hui is a very well-respected educator, optometrist, and researcher with the exact skill-set and background to serve as our Biosciences head. His outstanding knowledge of the ocular surface, combined with his extensive lecturing on ocular therapeutic drugs and a PhD in ocular drug delivery, aligns with our ongoing initiatives and mission. We are absolutely delighted to bring Alex back to Waterloo and are excited to have him lead the CORE Biosciences platform,” said Lyndon Jones, PhD, DSc, FCOptom, FAAO, CORE’s director.
Before joining UNSW in 2015, Dr. Hui completed his optometry training and PhD at the University of Waterloo School of Optometry & Vision Science and CORE. He is an author on more than 30 peer reviewed and non-peer reviewed publications and has been an invited speaker at conferences worldwide. In addition to drug delivery systems, his research has been focused on ocular therapeutics, myopia control, and contact lenses. Dr. Hui is also an associate editor for Clinical and Experimental Optometry.
“CORE has continued to build an international reputation for high quality research, which I’ve admired during my seven years in Australia,” said Dr. Hui. “It’s been a privilege to spend time with everyone at UNSW, and I’m excited about this new opportunity to work with a fantastic group of researchers and personnel back in Canada.”
CORE’s current Head of Biosciences Dr. William Ngo has been appointed as an assistant professor at the University of Waterloo’s School of Optometry & Vision Science, reflecting his ever-growing contributions to the field. He will continue to collaborate with CORE and its research team in his chosen area of ocular surface disease.
Source: CORE
